MPI | Jotup

Mussel Polymers, Inc. announces breakthrough in the treatment of sensitive teeth

Retrieved on:

Monday, October 3, 2022

Toothpaste, Dentin, PCS, Polymer, Adhesive, CEO, ACP, Multimedia, Pain, Dentistry, Temperature, Office, Purdue University, Tooth, Amorphous calcium phosphate, MPI

The patented MPI tooth sensitivity treatment is expected to be longer-lasting than currently used non-surgical treatments.

Key Points:

The patented MPI tooth sensitivity treatment is expected to be longer-lasting than currently used non-surgical treatments.
Dentin sensitivity is caused by the exposure of dentinal tubules, either by gum recession or loss of the outer layers of the teeth (enamel and cementum).
Mussel Polymers' new approach using Poly(Catechol-Styrene) is expected to provide longer-lasting pain relief than current treatments.
George Boyajian, CEO of Mussel Polymers, Inc said "Curing tooth sensitivity has been a challenge for the dental industry.

TUV Rheinland's North American Laboratory inspects half a million automotive parts in first 12 months

Retrieved on:

Wednesday, September 28, 2022

WEST UNITY, Ohio, Sept. 28, 2022 /PRNewswire/ -- The TÜV Rheinland North America laboratory in West Unity, Ohio has reached the first milestone in its 12 month history by performing 500,000 inspections of automotive parts, including pitman arms and steering knuckles. This has been achieved thanks to the work of our certified magnetic particle inspection (MPI) technicians.

Key Points:

WEST UNITY, Ohio, Sept. 28, 2022 /PRNewswire/ -- The TV Rheinland North America laboratory in West Unity, Ohio has reached the first milestone in its 12 month history by performing 500,000 inspections of automotive parts, including pitman arms and steering knuckles.
This has been achieved thanks to the work of our certified magnetic particle inspection (MPI) technicians.
In addition, the lab has automated Magnetic Particle Inspection (MPI) capabilities, which can efficiently process forgings with fast turnaround times.
Since 2006, TV Rheinland has been a member of the United Nations Global Compact to promote sustainability and combat corruption.

Mussel Polymers announces new multi-functional carbon and aramid fiber coating for stronger lighter reinforced composites

Retrieved on:

Wednesday, September 28, 2022

Carbon, Adhesive, Polymer, Adoption, Temperature, Carbon-fiber-reinforced polymers, PCS, MPI, PDA, Flexural strength, Shear strength, Dopamine, Lehigh University, Golf, Multimedia, Synthetic fiber, Thermoplastic

Mussel Polymers, Inc., a specialty materials and coatings company, announced today that it has successfully coated carbon and aramid fibers with its Poly(catechol-styrene) (PCS), which is a step forward in producing lighter, stronger fiber reinforced composites.

Key Points:

Mussel Polymers, Inc., a specialty materials and coatings company, announced today that it has successfully coated carbon and aramid fibers with its Poly(catechol-styrene) (PCS), which is a step forward in producing lighter, stronger fiber reinforced composites.
This application of PCS is likely to significantly increase the strength and impact energy of fiber reinforced materials and improve the use of coatings and adhesives with carbon fiber parts and materials.
While carbon and aramid fibers possess many positive attributes, they are notoriously difficult to bond with because they are smooth and chemically inert.
Jason Stieg Chief Commercial Officer of Mussel Polymers "The MPI team successfully coated carbon and aramid fibers with PCS using a simple one-step, room temperature process.

The Worldwide Milk Protein Isolate Industry is Expected to Reach $3.45 Billion by 2030 - ResearchAndMarkets.com

Retrieved on:

Wednesday, September 28, 2022

Food, Beverage, Retail, Human body, Infant, Organic acid, Food, Athlete, Parent, Population, Milk, Growth, Drink, MPI, MPI-CDG, IDFA, CAGR, Agriculture

Milk Protein Isolate is a protein product with a high protein content.

Key Points:

Milk Protein Isolate is a protein product with a high protein content.
The booming sports nutrition industry is a key driver of the Milk Protein Isolate market.
As per the International Dairy Foods Association (IDFA), the global milk protein isolate market is expected to witness a CAGR of around 6% from 2019 to 2025.
For the purpose of this report, the author have segmented into the global Milk Protein Isolate market on the basis of filtration method, application, distribution channel, and region:

Focus on Customers Continues with Idaho Milk Products’ Episode 6 ‘Replacing Caseinates in Beverages’

Retrieved on:

Tuesday, September 13, 2022

Cream, Pharmaceutical formulation, Episode VI, MPI, Knowledge, Farmer, Milk, Milk protein concentrate, History, Sales & Marketing Executives International, MBA, MPC, Solution, GLOBE, R, Phil Connolly, Drink, Adhesive

JEROME, I.D., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Idaho Milk Products will present Episode 6 in their Formulating with Milk Proteins webinar series on Cleaner Labels, Replacing Caseinates in Beverages.

Key Points:

JEROME, I.D., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Idaho Milk Products will present Episode 6 in their Formulating with Milk Proteins webinar series on Cleaner Labels, Replacing Caseinates in Beverages.
Speakers will include Phillip Connolly, Independent Consultant, Florian Middelhuis, MBA, Vice President of Sales & Marketing, Kumar Tammineedi, Senior Research & Product Development Scientist and Sachin Sharma, Research & Development Scientist at Idaho Milk Products.
Idaho Milk Products is a privately held, vertically integrated international milk processing leader, supplying Milk Protein Isolate (MPI), Milk Protein Concentrate (MPC), Milk Permeate, and Cream derivatives to customers around the globe.
Owned by local Idaho dairy farmers, Idaho Milk Products has a dedicated consistent milk supply and delivers reliable, quality dairy ingredients.

Bishop-McCann Named to 2022 MeetingsNet CMI 25 List; Recognized as One of North America’s Largest Meetings, Incentive Programs, and Events Agencies

Retrieved on:

Tuesday, September 13, 2022

Professional Services, Other Professional Services, Other Travel, Transportation, Lodging, Travel, MPI, Association, Industry, Travel, ASE Group, Meeting, Bishop, Board, Education, View, Trustee

MeetingsNet, a digital magazine and website dedicated to the meetings and incentives industry, has named Kansas City-based Bishop-McCann to its 2022 CMI 25 list, which highlights the largest and most influential corporate full-service meeting and incentive travel management companies in North America.

Key Points:

MeetingsNet, a digital magazine and website dedicated to the meetings and incentives industry, has named Kansas City-based Bishop-McCann to its 2022 CMI 25 list, which highlights the largest and most influential corporate full-service meeting and incentive travel management companies in North America.
This is the 15th year that Bishop-McCanna worldwide leader in the meetings, incentives, and events industryhas been included on this list.
We continue to create JOY for our clients by delivering the absolute best experiences, and were humbled to once again be named to this impressive industry list.
Adams serves on the Meetings Professional International (MPI) Board of Trustees, the worlds largest meetings and events industry association, and he was named one of the top 25 influencers in the meetings and events industry in 2019.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on:

Tuesday, September 13, 2022

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).

Key Points:

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).
Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on:

Tuesday, September 13, 2022

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.

Key Points:

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights.
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

Retrieved on:

Tuesday, September 6, 2022

FAIRFAX, Va., September 06, 2022 /PRNewswire-PRWeb/ -- The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to answer cardiac imagers' questions about SPECT/CT and PET/CT imaging with attenuation correction, localization of radiotracer uptake and coronary artery calcium scoring (CACS). In a new multisociety guideline published today in the Journal of Nuclear Cardiology, the organizations recommend training and competency requirements for imaging physicians and technologists; describe models for collaborative, cross-specialty study interpretation and reporting; and suggest solutions for the preauthorization and reimbursement challenges that some labs have faced with hybrid imaging in nuclear cardiology.

Key Points:

"Assessing atherosclerosis burden in hybrid imaging improves the diagnostic accuracy of MPI studies and help clinicians identify high-risk patients and treat them accordingly.
The question is not whether today's cardiac imaging labs should adopt hybrid imaging but rather how to adapt their labs for the routine use of SPECT/CT and PET/CT.
Imaging teams will find the new guideline is a blueprint for modernizing their labs for the delivery of hybrid nuclear-CT imaging.
ASNC's Hybrid Imaging Symposium will be delivered in two parts:
Part 1 is currently available OnDemand on the ASNC2022 online meeting platform.

New TEXT2DRIVE Study Reveals the Technology Consumers Want in Dealership Service Lane

Retrieved on:

Tuesday, August 16, 2022

Power learned that dealers capture 88 percent of customers' annual service visits in the first three years of ownership but what keeps them returning after that?

Key Points:

Power learned that dealers capture 88 percent of customers' annual service visits in the first three years of ownership but what keeps them returning after that?
Texting for the Win: The survey revealed that only one in three respondents are very familiar with their vehicle's factory-recommended maintenance schedule.
1 in 4 Say Service Experience Exceeded Expectations: Of respondents who had recently visited a dealership service lane, only one in four said their past experiences exceeded their expectations, while 57 percent of respondents said their servicing dealership met their expectations.
*Methodology: In March 2022, TEXT2DRIVE polled 1,000 U.S. drivers ages 26-67 who visited a dealerships service department in the last five years.